Abstract
Isocitrate dehydrogenase 1 (IDH1) mutations, which are early and frequent genetic alterations in astrocytomas, oligodendrogliomas, oligoastrocytomas, and secondary glioblastomas, are specific to arginine 132 (R132). Recently, we established monoclonal antibodies (mAbs) against IDH1 mutations: anti-IDH1-R132H and anti-IDH1-R132S. However, the importance of immunohistochemistry using the combination of those mAbs has not been elucidated. For this study, 164 cases of glioma were evaluated immunohistochemically for IDH1 mutations (R132H and R132S) using anti-IDH1 mAbs (HMab-1 and SMab-1). IDH1 mutation was detected, respectively, in 9.7%, 63.6%, 51.7%, and 77.8% of primary grade IV, secondary grade IV, grade III, and grade II gliomas. For each grade of glioma, prognostic factors for progression-free survival and overall survival were evaluated using clinical and pathological parameters in addition to IDH1 immunohistochemistry. IDH1 mutation, p53 overexpression, and internexin expression, as evaluated using immunohistochemistry with clinical parameters such as degree of surgical removal and preoperative Karnofsky Performance Status (KPS), might be of greater prognostic significance than histological grading alone in grade III as well as IDH1 mutation in grade IV gliomas.
Similar content being viewed by others
References
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773
Sonoda Y, Kumabe T, Nakamura T, Kanamori M, Yamashita Y, Suzuki H, Tominaga T (2009) Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci 100:1996–1998
Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149–1153
Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739–744
Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, yu W, Li Z, Gong L, Peng Y, Ding J, Lei Q, Guan KL, Xiong Y (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α. Science 324:261–265
Williams SC, Karajannis MA, Chiriboga L, Golfin JG, von Deimling A, Zagzag D (2011) R132H mutantion of isocitrate dehydrogenase-1 is not efficient for HIF-1alpha upregulation in adult glioma. Acta Neuropathol 121:274–281
Metellus P, Colin C, Taieb D, Guedj E, Nanni-Metellus I, de Paula AM, Colavolpe C, Fuentes S, Dufour H, Barrie M, Chinot O, Ouafik LH, Figarella-Branger D (2011) IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients. J Neurooncol 105(3):591–600
Kato Y, Jin G, Kuan CT, McLendon RE, Yan H, Bigner DD (2009) A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem Biophys Res Commun 390:547–551
Kaneko M, Tian W, Takano S, Suzuki H, Sawa Y, Hozumi Y, Goto K, Yamazaki K, Kitanaka C, Kato Y (2011) Establishment of a novel monoclonal antibody SMab-1 specific for IDH1 R132S mutation. Biochem Biophys Res Commun 406:608–613
Capper D, Zentqraf H, Balss J, Hartmann C, von Deimling A (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118:599–601
Takano S, Tian W, Matsuda M, Yamamoto T, Ishikawa E, Yamazaki K, Kato Y, Matsumura A (2011) Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol 28:115–123
Ducray F, Criniere E, Idbaih A, Mokhtari K, Maric Y, Paris S, Navarro S, Laigle-Donadey F, Dehais C, Thilet J, Hoang-Xuan K, Delattre JY, Sanson M (2009) Alpha-internexin expression identifies 1p19q codeleted gliomas. Neurology 72:156–161
Ducray F, Mokhtari K, Crinière E, Idbaih A, Marie Y, Dehais C, Paris S, Carpentier C, Dieme MJ, Adam C, Hoang-Xuan K, Duyckaerts C, Delattre JY, Sanson M (2011) Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas. Eur J Cancer 47:802–808
Durand K, Guillaudeau A, Pommepuy I, Mesturoux L, Chaunavel A, Gadeaud E, Porcheron M, Moreau JJ, Labrousse F (2011) Alpha-internexin in gliomas, relationship with histological type and 1p, 19q, 10p and 10q status. J Clin Pathol 64:793–801
Mokhtari K, Ducray F, Kros JM, Gorlia T, Idbaih A, Taphoom M, Wesseling P, Hoang-Xuan K, van den Bent M, sanson M (2011) Alpha-internexin expression predicts outcome IN anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy. Cancer 117:3014–3026
Preusser M, Wohrer A, Stary S, Hoftberger R, Streubel B, Hainfellner JA (2011) Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens. J Neuropathol Exp Neurol 70:715–723
Sonoda Y, Yokosawa M, Saito R, Kanamori M, Yamashita Y, Kumabe T, Watanabe M, Tominaga T (2010) O6-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma. Int J Clin Oncol 15:352–358
Christman M, Naegel G, Hom S, Krhan U, Wiewroft D, Sommer C, Kaima B (2010) MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. Int J Cancer 127:2106–2118
Momota H, narita Y, Matsushita Y, Miyakita Y, Shibui S (2010) p53 abnormality and tumor invasion in patients with malignant astrocytoma. Brain Tumor Pathol 27:95–101
Pardo FS, Hsu DW, Zeheb R, Efird JT, Okurief PG, Malkin DM (2004) Mutant, wild type, or overall p53 expression: freedom from clinical progression in tumours of astrocytic lineage. Br J Cancer 91:1678–1686
Kloosterhof NK, Bralte LB, Dubbink HJ, French PJ, van den Bent M (2011) Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol 12:83–91
Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisseller B, Mokhtari K, Hoang-Xuan K, Delattre JY (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150–4154
van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoom MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M (2010) IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European organization for research and treatment of cancer brain tumor group. Clin Cancer Res 16:1597–1604
Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenerger G, Weller M, Loeffler M, von Deimling A (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707–718
Gupta R, Webb-Myers R, Flanagan S, Buckland ME (2011) Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications. J Clin Pathol 64:835–844 (July 12 [Epub ahead of print])
Capper D, Weibert S, Balss J, Habel A, Meyer J, Jager D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann C (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245–254
Dubbink HJ, Taal W, van Marion R, Kros JM, van Heuvel I, Bromberg JE, Zonnenberg BA, Zonnenberg CB, Postma TJ, Gijtenbeek JM, Boogerd W, Groenendijk FH, Smitt PA, Dinjens WN, van den Bent MJ (2009) IDH1 mutations in astrocytomas predict survival but not response to temozolomide. Neurology 73:1792–1795
Thon N, Eigenbrod S, Kreth S, Lutz J, Tonn JC, Kretzschmar H, Peraud A, Kreth FW (2011) IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival. Cancer 118(2):452–460
Kim YH, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Nakazato Y, Tanaka Y, Vital A, Mariani L, Stawaski R, Watanabe T, de Girolami U, Kleihues P, Ohgaki H (2010) Molecular classification of low-grade diffuse glioma. Am J Pathol 177:2708–2714
Houillier C, Wang X, Kaloshi G, Mokhtari K, Guilevin R, Laffaire J, Paris S, Boisselier B, Idbah A, Laigle-Donadey F, Sanson M, Delattre JY (2010) IDH1 or IDH2 mutations predict longer survival and response to temozlomide in low-grade gliomas. Neurology 75:1560–1566
Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M, Vecht C, Karim AB, European Organization for Research and Treatment of Cancer Brain Tumor Cooperative Group, European Organization for Research and Treatment of Cancer Radiotherapy Cooperative Group (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:2076–2084
Metellus P, Coulibaly B, Colin C, de Paula AM, Vasiljevic A, Taieb D, Barlier A, Boisselier B, Mokhatari K, Wang XW, Loundou A, Chapon F, Pineau S, Ouafik L, Chinot O, Figarella-Branger D (2010) Absence of IDH mutation identifies a novel radiological and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 120:719–729
Baas IO, Mulder JW, Offerhaus GJ, Vogelstein B, Hamilton SR (1994) An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172:5–12
Ohgaki H, Kleihues P (2009) Genetic alterations and signaling pathway in the evolution of gliomas. Cancer Sci 100:2235–2241
Birner P, Toumangelova-Uzeir K, Natchev S, Guentchev M (2011) Expression of mutated isocitrate dehydrogenase-1 in gliomas is associated with p53 and EGFR expression. Folia Neuropathol 49:88–93
Kurtkaya-Yapicier O, Scheithauer BW, Hebrink D, James CD (2002) p53 in nonneoplastic central nervous system lesions: an immunohistochemical and genetic sequencing study. Neurosurgery 51:1246–1254
Yip S, Butterfield YS, Morozova O, Chittaranjan S, Blough MD, An J, Birol I, Chesnelong C, Chiu R, Chuah E, Corbett R, Docking R, Firme M, Hirst M, Jackman S, Karsan A, Li H, Louis DN, Maslova A, Moore R, Moradian A, Mungall KL, Perizzolo M, Qian J, Roldan G, Smith EE, Tamura-Wells J, Thiessen N, Varhol R, Weiss S, Wu W, Young S, Zhao Y, Mungall AJ, Jones SJ, Morin GB, Chan JA, Cairncross JG, Marra MA (2012) Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 226(1):7–16
Precusser M, Charles JR, Felsberg J, Reifenberger G, Hanou MF, Diserens AC, Stupp R, Gorlia T, Marosi C, Heizl H, Hainfellner JA, Hegi M (2008) Anti-O6-methylguanine-methytransferase (MGMT) immunohistochemistry in glioblastoma multiforme observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 18:520–532
Cao VT, Jung TY, Jung S, Jin SG, Moon KS, Kim IY, Kang SS, Park CS, Lee KH, Chae HJ (2009) The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastoma. Neurosurgery 65:866–875
Acknowledgments
We thank Yoshiko Tsukada, Makiko Miyakawa, Imi Saito, and Junko Aita for their excellent technical assistance. This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (S.T., Y.K., M.K.K.), Japan Brain Foundation (S.T.), The Japanese Foundation for research and promotion of endoscopy (S.T.), Japanese Foundation for Multidisciplinary Treatment of Cancer (S.T.), Mitsubishi Pharma Research Foundation (Y.K., M.K.K.), Children Cancer Association of Japan (Y.K.), Intelligent Cosmos Academic Foundation (Y.K.), and Office for Gender Equality of Yamagata University (M.K.K.).
Author information
Authors and Affiliations
Corresponding authors
Additional information
Shingo Takano and Yukinari Kato contributed equally to this work.
Rights and permissions
About this article
Cite this article
Takano, S., Kato, Y., Yamamoto, T. et al. Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors. J Neurooncol 108, 361–373 (2012). https://doi.org/10.1007/s11060-012-0837-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-012-0837-0